BNP Paribas Decreases Stake in Bristol Myers Squibb Company $BMY

BNP Paribas trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 36,085 shares of the biopharmaceutical company’s stock after selling 27,033 shares during the quarter. BNP Paribas’ holdings in Bristol Myers Squibb were worth $1,627,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BMY. Vanguard Group Inc. increased its holdings in Bristol Myers Squibb by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after purchasing an additional 1,058,803 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares during the last quarter. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $1,554,154,000. Ameriprise Financial Inc. increased its stake in shares of Bristol Myers Squibb by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after buying an additional 432,158 shares during the last quarter. Finally, Independent Franchise Partners LLP raised its holdings in Bristol Myers Squibb by 20.6% in the second quarter. Independent Franchise Partners LLP now owns 20,976,954 shares of the biopharmaceutical company’s stock valued at $971,023,000 after acquiring an additional 3,583,163 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BMY shares. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Scotiabank reaffirmed a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research note on Wednesday, December 3rd. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, HSBC reaffirmed a “hold” rating and set a $53.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $61.00.

Bristol Myers Squibb Price Performance

BMY opened at $59.02 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The company’s 50-day moving average price is $58.24 and its 200 day moving average price is $51.46. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.